

Fairview Ridges Hospital 2008 Antibiotic Susceptibility Report

INPATIENT ANTIBIOGRAM - GRAM-POSITIVE ORGANISMS 2008												
(all cultures sent from any inpatient area)												
08 = 2008 data; ↓ = increase or decrease ≥ 5% in % susceptibility vs. 2007												
Numbers as expressed as % susceptible strains; NT = Not tested; blank = not enough isolates to report data												
NR=Not Recommended												
Gram-Positive Organisms	Strep. pneumoniae		Staph. aureus: MSSA		Staph. aureus: MRSA		Coagulase Negative Staph		Enterococcus faecalis		Enterococcus faecium	
	07	08	07	08	07	08	07	08	07	08	07	08
Year	07	08	07	08	07	08	07	08	07	08	07	08
No. Isolates	11	7	94	80	116	88	65	41	53	47	26	26
Ampicillin	NT	NT	NT	NT	NT	NT	NT	NT	100	100	15	19
Cefazolin	NT	NT	96	NT	NT	NT	29	NT	NT	NT	NT	NT
Cephalosporins-Gen 3	100*	100*	98	100	NT	NT	30	26	NT	NT	NT	NT
Clindamycin	90	↓57	80	↓75	19	24	61	59	NT	NT	NT	NT
Erythromycin	82	↓29	68	71	5	10	41	46	NT	NT	NT	NT
Levofloxacin	100	100	88	86	18	17	53	41	NR	NR	NR	NR
Linezolid	NT	NT	100	100	100	100	100	100	100	98	96	100
Penicillin G	82	↓33	20	23	0	2	6	10	100	100	15	19
Tetracycline	91	↓43	98	99	99	100	75	90	26	28	50	35
Trimeth/Sulfa (Bactrim)	82	↓57	100	100	98	100	75	80	NT	NT	NT	NT
Vancomycin	100	100	100	100	100	100	100	100	98	98	42	19

*Reported as combined sensitivity to ceftriaxone & cefotaxime. Other cephalosporins will be more resistant.

2008 MRSA breakdown: 52% of Staph.aureus isolates are MRSA

INPATIENT ANTIBIOGRAM - GRAM-NEGATIVE ORGANISMS 2008

(all cultures sent from any inpatient area)

08 = 2008 data; ↓ = increase or decrease ≥ 5% in % susceptibility vs. 2007

Numbers as expressed as % susceptible strains; NT = Not tested; blank = not enough isolates to report data; NR= Not Recommended

Gram-Negative Bacilli	<i>Enterobacter cloacae</i>		<i>Escherichia coli</i>		<i>Klebsiella oxytoca</i>		<i>Klebsiella pneumoniae</i>		<i>Proteus mirabilis</i>		<i>Pseudomonas aeruginosa</i>		<i>Serratia marcescens</i>		<i>Stenotrophomonas maltophilia</i>	
	07	08	07	08	07	08	07	08	07	08	07	08	07	08	07	08
Year	07	08	07	08	07	08	07	08	07	08	07	08	07	08	07	08
# Isolates	13	17	128	126	11	13	36	48	17	20	50	49	13	10	8	4
Ampicillin	NT	NT	59	67	0	0	0	0	82	95	NT	NT	NT	NT	NT	NT
Ampicillin/Sulbactam (Unasyn)	0	0	77	83	91	↓77	100	100	82	95	NT	NT	0	0	NT	NT
Cefazolin	NT	NT	90	94	64	↓46	100	100	76	95	NT	NT	NT	NT	NT	NT
Ceftazidime	77	100 [^]	98	99	100	100	100	100	94	95	84	88	100 [^]	100 [^]	63	↓25
Ceftriaxone	77	100 [^]	98	99	100	100	100	100	94	95	NT	NT	100 [^]	100	NT	NT
Ciprofloxacin	85	88	86	↓80	100	100	89	100 [^]	53	90	78	↓71	54	100 [^]	25	25
Gentamicin	85	88	96	97	100	100	100	100	82	100	82	96	100	100		
Imipenem	100	100	100	100	100	100	100	100			92	96	100	100		
Levofloxacin	100	↓88	87	↓82	100	100	89	100 [^]	71	95	78	↓73	62	100 [^]		
Meropenem		100		100		100		100		100		100		100		
Piperacillin	89	↓81	79	79	50	↓0	0	0	83	100	88	98	89	100 [^]	25	25
Piperacillin/tazobactam (Zosyn)	100	100	100	100	100	100	100	100	100	100	94	98	89	100 [^]		
Ticarcillin/Clavulanic (Timentin)	82	94	90	88	91	↓85	100	100	100	100	78	78	77	100 [^]	50	50
Tobramycin	85	88	96	97	100	100	100	100	82	100	100	100	100	100		
Trimeth/Sulfa (Bactrim)	85	82	84	84	100	100	94	96	82	95	25	NT	100	100	100	100

[^]Enterobacter and Serratia may develop resistance during prolonged therapy with 3rd-generation cephalosporins. Isolates that are initially susceptible may become resistant within 3-4 days